Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1564-1577
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1564
Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription
Sai-Nan Li, Shan Yang, Hao-Qi Wang, Tian-Li Hui, Meng Cheng, Xi Zhang, Bao-Kun Li, Gui-Ying Wang
Sai-Nan Li, Shan Yang, Hao-Qi Wang, Tian-Li Hui, Meng Cheng, Xi Zhang, The First Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Sai-Nan Li, Bao-Kun Li, Gui-Ying Wang, The Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Gui-Ying Wang, Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Author contributions: Li SN and Wang GY contributed to conception, design and writing of the manuscript; Li SN, Hui TL, Yang S, Zhang X and Wang HQ performed the research; Cheng M, Li BK and Li SN contributed to analysis and interpretation of data; and all authors read and approved the final manuscript.
Supported by Hebei Provincial Health Commission Youth Science and Technology Project, No. 20210027.
Institutional review board statement: The study was reviewed and approved by the Fourth Yuan Medical Ethics Committee of Hebei Medical University, No. 2023KS025.
Institutional animal care and use committee statement: All experiments with designed animals were reviewed and approved by the Ethics Committee for Laboratory Animal Welfare of the Fourth Hospital of Hebei Medical University, No. IACUC-4th Hos Hebmu-.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data are available from the corresponding author.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines and have prepared and revised the manuscript according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gui-Ying Wang, PhD, Surgeon, Department of General Surgery, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang 050000, Hebei Province, China. hebeiwangguiying@163.com
Received: December 22, 2023
Peer-review started: December 22, 2023
First decision: January 9, 2024
Revised: January 26, 2024
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: April 15, 2024
Processing time: 111 Days and 0.8 Hours
Core Tip

Core Tip: The revelation that long noncoding RNA prion protein testis specific, which is overexpressed in oxaliplatin-resistant colorectal cancer (CRC) cells, regulates the expression of homeodomain interacting protein kinase 2 by sponging transcription factor zinc finger protein 184 unveils a promising target for enhancing the efficacy of chemotherapy. This mechanistic insight could lead to the development of novel therapeutic strategies to combat resistance in CRC treatments.